What is the current valuation of the point-of-care molecular diagnostics market in South Korea?

The market valuation was $156.19 Million in 2024. Read More

What is the projected market size for point-of-care molecular diagnostics in South Korea by 2035?

The market is projected to reach $375.0 Million by 2035. Read More

Which companies are the key players in the South Korea point-of-care molecular diagnostics market?

Key players include Abbott Laboratories, Roche Diagnostics, Cepheid, Thermo Fisher Scientific, Hologic Inc., Qiagen N.V., Becton Dickinson and Company, and GenMark Diagnostics. Read More

What was the market value for Infectious Diseases in the South Korea point-of-care molecular diagnostics market in 2024?

The market value for Infectious Diseases was $60.0 Million in 2024. Read More

How much is the market for Nucleic Acid Amplification Tests expected to grow by 2035?

The market for Nucleic Acid Amplification Tests is projected to grow from $40.0 Million in 2024 to $90.0 Million by 2035. Read More

What is the expected market value for Diagnostic Laboratories in the South Korea point-of-care molecular diagnostics market?

The expected market value for Diagnostic Laboratories is projected to increase from $50.0 Million in 2024 to $120.0 Million by 2035. Read More

Which technology segment is anticipated to have the highest growth in the South Korea point-of-care molecular diagnostics market?

The Polymerase Chain Reaction segment is anticipated to grow from $60.0 Million in 2024 to $150.0 Million by 2035. Read More

What was the market value for Other Genetic Tests in 2024?

The market value for Other Genetic Tests was $41.19 Million in 2024. Read More

South Korea Point of Care Molecular Diagnostics Market

Q: What is the expected CAGR for the South Korea point-of-care molecular diagnostics market during the forecast period 2025 - 2035?

The expected CAGR is 8.29% during the forecast period 2025 - 2035. Read More

Q: What are the main application segments for point-of-care molecular diagnostics in South Korea?

Main application segments include Infectious Diseases, Genetic Testing, Cancer Diagnosis, and Metabolic Disorders. Read More

ID: MRFR/MED/49957-HCR

200 Pages

Rahul Gotadki

Last Updated: February 06, 2026

South Korea Point-of-care Molecular Diagnostics Market Research Report: Size, Share, Trend Analysis By Product Type (PCR Tests, Nucleic Acid Amplification Tests, Microarray, Next-Generation Sequencing, Other Genetic Tests), By Applications (Infectious Diseases, Genetic Testing, Cancer Diagnosis, Metabolic Disorders), By End-use (Hospitals, Diagnostic Laboratories, Home Care Settings, Outpatient Clinics), and By Technology (Isothermal Amplification, Polymerase Chain Reaction, Sanger Sequencing, CRISPR Technology) - Growth Outlook & Industry Forecast 2025 To 2035

South Korea Point of Care Molecular Diagnostics Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Pharmaceutical, BY Type (USD Million)
  1. 4.1.1 PCR Tests
  2. 4.1.2 Nucleic Acid Amplification Tests
  3. 4.1.3 Microarray
  4. 4.1.4 Next-Generation Sequencing
  5. 4.1.5 Other Genetic Tests
2. 4.2 Pharmaceutical, BY Application (USD Million)
  1. 4.2.1 Infectious Diseases
  2. 4.2.2 Genetic Testing
  3. 4.2.3 Cancer Diagnosis
  4. 4.2.4 Metabolic Disorders
3. 4.3 Pharmaceutical, BY End Use (USD Million)
  1. 4.3.1 Hospitals
  2. 4.3.2 Diagnostic Laboratories
  3. 4.3.3 Home Care Settings
  4. 4.3.4 Outpatient Clinics
4. 4.4 Pharmaceutical, BY Technology (USD Million)
  1. 4.4.1 Isothermal Amplification
  2. 4.4.2 Polymerase Chain Reaction
  3. 4.4.3 Sanger Sequencing
  4. 4.4.4 CRISPR Technology
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Pharmaceutical
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Abbott Laboratories (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Roche Diagnostics (CH)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Cepheid (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Thermo Fisher Scientific (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Hologic Inc. (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Qiagen N.V. (NL)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Becton Dickinson and Company (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 GenMark Diagnostics (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 SOUTH KOREA MARKET ANALYSIS BY TYPE
3. 6.3 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
4. 6.4 SOUTH KOREA MARKET ANALYSIS BY END USE
5. 6.5 SOUTH KOREA MARKET ANALYSIS BY TECHNOLOGY
6. 6.6 KEY BUYING CRITERIA OF PHARMACEUTICAL
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF PHARMACEUTICAL
9. 6.9 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
10. 6.10 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
11. 6.11 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
12. 6.12 PHARMACEUTICAL, BY TYPE, 2024 (% SHARE)
13. 6.13 PHARMACEUTICAL, BY TYPE, 2024 TO 2035 (USD Million)
14. 6.14 PHARMACEUTICAL, BY APPLICATION, 2024 (% SHARE)
15. 6.15 PHARMACEUTICAL, BY APPLICATION, 2024 TO 2035 (USD Million)
16. 6.16 PHARMACEUTICAL, BY END USE, 2024 (% SHARE)
17. 6.17 PHARMACEUTICAL, BY END USE, 2024 TO 2035 (USD Million)
18. 6.18 PHARMACEUTICAL, BY TECHNOLOGY, 2024 (% SHARE)
19. 6.19 PHARMACEUTICAL, BY TECHNOLOGY, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY APPLICATION, 2025-2035 (USD Million)
  3. 7.2.3 BY END USE, 2025-2035 (USD Million)
  4. 7.2.4 BY TECHNOLOGY, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

South Korea Pharmaceutical Market Segmentation

Pharmaceutical By Type (USD Million, 2025-2035)

PCR Tests
Nucleic Acid Amplification Tests
Microarray
Next-Generation Sequencing
Other Genetic Tests

Pharmaceutical By Application (USD Million, 2025-2035)

Infectious Diseases
Genetic Testing
Cancer Diagnosis
Metabolic Disorders

Pharmaceutical By End Use (USD Million, 2025-2035)

Hospitals
Diagnostic Laboratories
Home Care Settings
Outpatient Clinics

Pharmaceutical By Technology (USD Million, 2025-2035)

Isothermal Amplification
Polymerase Chain Reaction
Sanger Sequencing
CRISPR Technology

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”